Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) fell 8.3% during mid-day trading on Thursday . The company traded as low as C$0.11 and last traded at C$0.11. 240,655 shares were traded during trading, an increase of 150% from the average session volume of 96,162 shares. The stock had previously closed at C$0.12.
Hemostemix Trading Up 13.6 %
The firm has a 50 day moving average of C$0.08 and a two-hundred day moving average of C$0.07. The stock has a market capitalization of C$10.89 million, a PE ratio of -6.25 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
- Election Stocks: How Elections Affect the Stock Market
- Nebius Group: The Rising Star in AI Infrastructure
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- MarketBeat Week in Review – 12/30 – 1/03
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
